WAYNE, Pa., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the second quarter ended June 30, 2019.
Second quarter 2019 net revenues were $652.5 million, an increase of 7% compared to the prior year period. Excluding the impact of foreign currency exchange rate fluctuations, second quarter 2019 net revenues increased 9.6% over the year ago period.
Second quarter 2019 GAAP earnings per share from continuing operations were $1.77, compared to GAAP earnings per share of ($0.06) in the prior year period. Second quarter 2019 adjusted diluted earnings per share from continuing operations increased 7.7% to $2.66, compared to $2.47 in the prior year period.
Liam Kelly, President and Chief Executive Officer, said, “In the second quarter of 2019 we accelerated our growth rate from the first quarter, delivering 9.6% constant currency revenue growth. We continue to see strength across nearly every global product category, with Interventional Urology, Vascular Access, Surgical, and Interventional each producing strong results. Based on the momentum we've generated during the first six months of the year, as well as our outlook for the remainder of the year, we are increasing our full year constant currency revenue growth guidance from a range of between 6% and 7%, to a range of between 7.5% and 8%."
Mr. Kelly continued, "The increase in our constant currency revenue growth expectations are due to a multitude of Teleflex products, including increased expectations for our Interventional Urology products, as UroLift continues to generate robust physician adoption, generating $67.9 million in second quarter revenues, up 42.7% on a constant currency basis compared to the prior year period. Based on its strong performance in the first half of the year, we are increasing our UroLift full year 2019 revenue growth guidance from approximately 30% to approximately 35%."
Mr. Kelly concluded, "In addition to strong second quarter top-line performance, second quarter adjusted diluted earnings per share increased 7.7%. Finally, despite worsening headwinds from foreign currency exchange rate volatility as compared to our initial expectations, we are reaffirming our full year adjusted diluted earnings per share guidance range of between $10.90 and $11.10."
NET REVENUE BY SEGMENT
The following table provides information regarding net revenues in each of the Company's reportable operating segments for the three and six months ended June 30, 2019 and July 1, 2018 on both a GAAP and constant currency basis. The discussion below the table of the principal factors behind changes in net revenues for the three months ended June 30, 2019 as compared to the prior year period applies to both GAAP revenue and constant currency revenue, although GAAP revenue also was affected by foreign currency exchange rate fluctuations, as indicated in the "Currency Impact" column of the table.
Americas second quarter 2019 net revenues were $373.8 million, an increase of 12.8% compared to the prior year period. Excluding the impact of foreign currency exchange rate fluctuations, second quarter 2019 net revenues increased 13.1% compared to the prior year period. The increase in constant currency revenue is primarily attributable to an increase in sales volumes of existing products.
EMEA second quarter 2019 net revenues were $147.1 million, a decrease of 4.2% compared to the prior year period. Excluding the impact of foreign currency exchange rate fluctuations, second quarter 2019 net revenues increased 1.9% compared to the prior year period. The increase in constant currency revenue is primarily attributable to an increase in new product sales and revenues generated by acquired businesses.
Asia second quarter 2019 net revenues were $75.2 million, an increase of 3.9% compared to the prior year period. Excluding the impact of foreign currency exchange rate fluctuations, second quarter 2019 net revenues increased 10.0% compared to the prior year period. The increase in constant currency revenue is primarily attributable to an increase in sales volumes of existing products, an increase in new product sales, and revenue generated by an acquired business.
OEM second quarter 2019 net revenues were $56.4 million, an increase of 7.3% compared to the prior year period. Excluding the impact of foreign currency exchange rate fluctuations, second quarter 2019 net revenues increased 8.5% compared to the prior year period. The increase in constant currency revenue is primarily attributable to an increase in sales volumes of existing products.
NET REVENUE BY GLOBAL PRODUCT CATEGORY
The following table and commentary provides information regarding net revenues in each of the Company's global product categories for the three and six months ended June 30, 2019 and July 1, 2018 on both a GAAP and constant currency basis.
Second quarter 2019 net revenues from sales of Vascular Access products were $153.6 million, an increase of 9.6% compared to the prior year period. Excluding the impact of foreign currency exchange rate fluctuations, second quarter 2019 net revenues increased 12% compared to the prior year period.
Second quarter 2019 net revenues from sales of Interventional products were $104.8 million, an increase of 6.7% compared to the prior year period. Excluding the impact of foreign currency exchange rate fluctuations, second quarter 2019 net revenues increased 8.8% compared to the prior year period.
Second quarter 2019 net revenues from sales of Anesthesia products were $85.7 million, a decrease of 4.0% compared to the prior year period. Excluding the impact of foreign currency exchange rate fluctuations, second quarter 2019 net revenues decreased 0.9% compared to the prior year period.
Second quarter 2019 net revenues from sales of Surgical products were $95.6 million, an increase of 5.6% compared to the prior year period. Excluding the impact of foreign currency exchange rate fluctuations, second quarter 2019 net revenues increased 9% compared to the prior year period.
Second quarter 2019 net revenues from sales of Interventional Urology products were $67.9 million, an increase of 42.5% compared to the prior year period. Excluding the impact of foreign currency exchange rate fluctuations, second quarter 2019 net revenues increased 42.7% compared to the prior year period.
Second quarter 2019 net revenues from sales of OEM products were $56.4 million, an increase of 7.3% compared to the prior year period. Excluding the impact of foreign currency exchange rate fluctuations, second quarter 2019 net revenues increased 8.5% compared to the prior year period.
Second quarter 2019 net revenues from sales of other products were $88.4 million, a decrease of 3.3% compared to the prior year period. Excluding the impact of foreign currency exchange rate fluctuations, second quarter 2019 net revenues increased 0.3% compared to the prior year period.
OTHER FINANCIAL HIGHLIGHTS AND KEY PERFORMANCE METRICS
Depreciation expense, amortization of intangible assets and deferred financing charges for the first six months of 2019 totaled $109.5 million compared to $106.9 million for the prior year period.
Cash and cash equivalents at June 30, 2019 were $303.9 million compared to $357.2 million at December 31, 2018.
Net accounts receivable at June 30, 2019 were $382.1 million compared to $366.3 million at December 31, 2018.
Net inventories at June 30, 2019 were $461.3 million compared to $427.8 million at December 31, 2018.
2019 OUTLOOK
The Company raised its full year 2019 revenue guidance range from an increase of between 5% and 6% over the prior year on a GAAP basis, to a range of between 6% and 6.5% over the prior year on a GAAP basis. The Company increased its estimate of the unfavorable impact of foreign currency exchange rate fluctuations on full year 2019 revenues from approximately 1% to approximately 1.5%. The Company raised its full year 2019 revenue guidance on a constant currency basis from a range of between 6% and 7%, to a range of between 7.5% and 8%.
The Company raised its full year 2019 GAAP diluted earnings per share from continuing operations guidance from a range of between $6.72 and $6.84 to a range of between $6.82 and $6.94. The Company reaffirmed adjusted diluted earnings per share from continuing operations to be between $10.90 and $11.10 for full year 2019, representing an increase of between 10.1% and 12.1% over 2018, and reflecting our estimate of an approximately 3.5% negative impact from foreign currency exchange rate fluctuations.
ABOUT TELEFLEX INCORPORATED
Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation - a relentless pursuit of identifying unmet clinical needs - to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular access, interventional cardiology and radiology, anesthesia, emergency medicine, surgical, urology and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit teleflex.com.

